Acquired amegakaryocytic thrombocytopenia after durvalumab administration

Immune checkpoint inhibitors (ICIs), despite their ability to potentiate antitumor T-cell responses, may cause various immune-related adverse events. Most cases of thrombocytopenia induced by ICIs have revealed a pathophysiologic mechanism of immune thrombocytopenia with increased platelet destructi...

Descripción completa

Detalles Bibliográficos
Autores principales: Suyama, Takahiro, Hagihara, Masao, Kubota, Naoto, Osamura, Yoshiyuki, Shinka, Yoko, Miyao, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053569/
https://www.ncbi.nlm.nih.gov/pubmed/33431742
http://dx.doi.org/10.3960/jslrt.20047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053569/
https://www.ncbi.nlm.nih.gov/pubmed/33431742
http://dx.doi.org/10.3960/jslrt.20047

Ejemplares similares